MET and renal carcinoma: There are various recent clinical trials that have already demonstrated the effect of MET inhibitors in patients with a variety of advanced or metastatic tumors, including non-small-cell lung cancer, and breast, prostate, liver, and renal cancer.[10] The aim of this study is to determine the frequency and prognostic value of MET gene mutation, amplification, and protein expression in OPSCC.